BioAge Labs Change in Accounts Payable 2024-2025 | BIOA

BioAge Labs change in accounts payable from 2024 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

BioAge Labs Change in Accounts Payable 2024-2025 | BIOA

BioAge Labs change in accounts payable from 2024 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.1B
Amgen (AMGN)$155.2B
Gilead Sciences (GILD)$148.2B
Vertex Pharmaceuticals (VRTX)$94B
Bristol Myers Squibb (BMY)$93.5B
CSL (CSLLY)$82.7B
GSK (GSK)$77.1B
Regeneron Pharmaceuticals (REGN)$59.7B
Alnylam Pharmaceuticals (ALNY)$57.5B
Argenex SE (ARGX)$40.5B
BioNTech SE (BNTX)$26.8B
Insmed (INSM)$23.2B
Royalty Pharma (RPRX)$21.1B
Biogen (BIIB)$19.2B
Incyte (INCY)$15.3B
Illumina (ILMN)$14.5B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$13.7B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Moderna (MRNA)$10.2B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$7.9B
Roivant Sciences (ROIV)$7.8B
Exact Sciences (EXAS)$7.8B
Halozyme Therapeutics (HALO)$7.8B